NEJM:Ribociclib+氟维司群可改善晚期乳腺癌患者生存期

2019-12-12 MedSci MedSci原创

研究认为,在激素受体阳性、HER 2阴性的晚期乳腺癌患者中,Ribociclib+氟维司群可显著提高患者的总体生存率

在涉及激素受体阳性、人表皮生长因子受体2(HER2)阴性的绝经后晚期乳腺癌患者的III期研究中,早期分析显示Ribociclib+氟维司群可显著提高患者无进展生存率。近日研究人员报告了第二次中期生存分析的结果。

参与研究的患者在氟维司群基础上,随机接受Ribociclib或安慰剂作为一线或二线治疗手段,研究的主要终点为生存率。

总计275例死亡病例,其中484例接受Ribociclib治疗的患者中167例(34.5%)死亡,242名接受安慰剂治疗的患者中108名(44.6%)死亡。Ribociclib+氟维司群的总体生存率明显高于氟维司群单独治疗。在42个月时,ribociclib组生存率为57.8%,安慰剂组为45.9%,相对死亡风险差异为28%(危险比0.72)。以ribociclib为一线治疗手段患者的中位无进展生存期组为33.6个月,安慰剂组为19.2个月。没有观察到新的安全事件。

研究认为,在激素受体阳性、HER 2阴性的晚期乳腺癌患者中,Ribociclib+氟维司群可显著提高患者的总体生存率。

原始出处:

Dennis J. Slamon et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med, December 11, 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1932666, encodeId=c6f41932666f8, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Jul 14 11:57:00 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378234, encodeId=41e913e82347d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Dec 14 09:57:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488584, encodeId=02481488584bf, content=<a href='/topic/show?id=bc7a1545e44' target=_blank style='color:#2F92EE;'>#ribociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15457, encryptionId=bc7a1545e44, topicName=ribociclib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f558440263, createdName=般若傻瓜, createdTime=Sat Dec 14 09:57:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571190, encodeId=a6c515e119064, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Dec 14 09:57:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035045, encodeId=bb371035045b5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Dec 12 21:57:00 CST 2019, time=2019-12-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1932666, encodeId=c6f41932666f8, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Jul 14 11:57:00 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378234, encodeId=41e913e82347d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Dec 14 09:57:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488584, encodeId=02481488584bf, content=<a href='/topic/show?id=bc7a1545e44' target=_blank style='color:#2F92EE;'>#ribociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15457, encryptionId=bc7a1545e44, topicName=ribociclib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f558440263, createdName=般若傻瓜, createdTime=Sat Dec 14 09:57:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571190, encodeId=a6c515e119064, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Dec 14 09:57:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035045, encodeId=bb371035045b5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Dec 12 21:57:00 CST 2019, time=2019-12-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1932666, encodeId=c6f41932666f8, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Jul 14 11:57:00 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378234, encodeId=41e913e82347d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Dec 14 09:57:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488584, encodeId=02481488584bf, content=<a href='/topic/show?id=bc7a1545e44' target=_blank style='color:#2F92EE;'>#ribociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15457, encryptionId=bc7a1545e44, topicName=ribociclib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f558440263, createdName=般若傻瓜, createdTime=Sat Dec 14 09:57:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571190, encodeId=a6c515e119064, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Dec 14 09:57:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035045, encodeId=bb371035045b5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Dec 12 21:57:00 CST 2019, time=2019-12-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1932666, encodeId=c6f41932666f8, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Jul 14 11:57:00 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378234, encodeId=41e913e82347d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Dec 14 09:57:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488584, encodeId=02481488584bf, content=<a href='/topic/show?id=bc7a1545e44' target=_blank style='color:#2F92EE;'>#ribociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15457, encryptionId=bc7a1545e44, topicName=ribociclib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f558440263, createdName=般若傻瓜, createdTime=Sat Dec 14 09:57:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571190, encodeId=a6c515e119064, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Dec 14 09:57:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035045, encodeId=bb371035045b5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Dec 12 21:57:00 CST 2019, time=2019-12-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1932666, encodeId=c6f41932666f8, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Jul 14 11:57:00 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378234, encodeId=41e913e82347d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Dec 14 09:57:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488584, encodeId=02481488584bf, content=<a href='/topic/show?id=bc7a1545e44' target=_blank style='color:#2F92EE;'>#ribociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15457, encryptionId=bc7a1545e44, topicName=ribociclib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f558440263, createdName=般若傻瓜, createdTime=Sat Dec 14 09:57:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571190, encodeId=a6c515e119064, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Dec 14 09:57:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035045, encodeId=bb371035045b5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Dec 12 21:57:00 CST 2019, time=2019-12-12, status=1, ipAttribution=)]
    2019-12-12 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

别老“做头发”,小心乳腺癌

染发增加癌症相对风险的实锤?速点!

Lancet:早期乳腺癌保乳手术后放疗方案的选择

研究认为,早期乳腺癌患者接受保乳手术后应采用全乳放疗作为复发的预防手段

21基因复发评分(RS)高者早期乳腺癌内分泌治疗联合辅助化疗获益

TAILORx是一项前瞻性随机对照研究,旨在评估21基因复发评分(RS)在激素受体阳性、HER2阴性、腋窝淋巴结阴性乳腺癌中的治疗预测作用。结果表明:RS评分11~25的总体人群中,单独内分泌治疗非劣效于辅助化疗联合内分泌治疗;但此组年龄是一个独立预后因素,探索性分析显示年龄≤50岁且RS评分为16~25的患者化疗有获益;该研究还显示如果RS评分为0~10无论年龄5年和9年的远处复发率很低,分别为

CDK4/6抑制剂前途,乳腺癌免疫疗法值得期待

ABC共识囊括了逆转肿瘤耐药的药物以及更多用于进展期乳腺癌的治疗方法。目前临床面临很多挑战,即部分患者在治疗一段时间后,肿瘤会对临床治疗用药产生耐药。而研究发现一些新药能够逆转肿瘤耐药现象,增加进展期乳腺癌患者的缓解率、疾病控制时间以及总生存期。这告诉我们,理解疾病的生理进程和生物靶点是很重要的,这可以帮助我们改善对疾病的疗法,随着对乳腺癌的进一步了解,我相信未来这是一个可以治愈的疾病。

乳腺癌合并甲状腺肿瘤患者,妥妥双靶帮助实现pCR乳腺癌合并甲状腺肿瘤患者,妥妥双靶帮助实现pCR

新辅助治疗是目前的研究热点,对于HER2阳性乳腺癌患者,曲妥珠单抗+帕妥珠单抗的联合方案用于新辅助治疗,能够更好的帮助具有保乳意愿的患者缩小肿瘤,实现保乳目标,甚至达到pCR,并有机会实现治愈的目的。

罗氏乳腺癌创新靶向药帕捷特®又一适应症在中国获批,开启HER2阳性晚期乳腺癌治疗新格局

罗氏制药中国近日宣布,中国国家药品监督管理局(NMPA)正式批准了帕捷特®(帕妥珠单抗)联合赫赛汀®(曲妥珠单抗)和多西他赛联用于尚未接受抗HER2治疗或化疗的HER2阳性转移性乳腺癌患者的一线标准治疗方案。该方案的获批,实现了我国HER2阳性晚期乳腺癌患者治疗方案的逐步国际化,将为HER2阳性晚期乳腺癌患者带来更久的生存获益,有助于实现乳腺癌诊疗的慢病化管理,使晚期乳腺癌摆脱“绝症”成为可能。帕